Primary Care Would Benefit from Education on Use of SGLT-2 Inhibitors, GLP-1 Mimetics: Nisa Maruthur, MD, MHS

Primary care clinicians are becoming more comfortable with prescribing "newer agents" to treat their patients with type 2 diabetes (T2D), but in a recent conversation with Patient Care®, Nisa Maruthur, MD, MHS, emphasized that additional education would be beneficial, on the cardiorenal protective benefits of the sodium-glucose cotransporter-2 inhibitors and the weight loss properties of the glucagon-like peptide-1 receptor agonists.

Maruthur, a primary care physician and associate professor of medicine, epidemiology, and nursing at Johns Hopkins University, also participated in development of the new American Diabetes Association/European Association for the Study of Diabetes consensus report on management of hyperglycemia which includes recommendations to agressively manage all the elements of cardiometabolic dysfunction that commonly present in patients with T2D. She discusses the education component, here.


For more conversations with Dr Maruthur:

ADA, EASD 2022 Consensus Report from the Primary Care Point of View, with Nisa Maruthur, MD, MHS

ADA/EASD Calls for Wide Systemic Change to Address Impact of Social Determinants of Health


Nisa M Maruthur, MD, MHS, is associate professor of medicine, epidemiology, and nursing at Johns Hopkins University and director of the general internal medicine fellowship program, at Johns Hopkins Medicine, in Baltimore, MD. Dr Maruthur also conducts clinical research in diabetes with a focus on diabetes prevention. She is particularly interetsetd in community-based approaches to improving diabetes outcomes and in individualized medicine.